Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer Raja Flores, MD, Thomas Bauer, MD, Ralph.

Slides:

Advertisements

Similar presentations

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma Kimberly S. Grant, MD,

Advertisements

Stephen R. Broderick, MD, MPHS

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Survival after Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy Emanuela Taioli, MD, PhD,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Lung cancer screening: No more excuses

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules Nasser K. Altorki, MD, Rowena Yip, MPH, Takaomi Hanaoka,

The effect of center volume on the incidence of postoperative complications and their impact on survival after lung transplantation Arman Kilic, MD,

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients Björn.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Survival after resection of synchronous non–small cell lung cancer

Accounting for outcomes: Lies, damned lies, and statistics

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Andrea S. Wolf, MD, MPH, Scott J

William M. DeCampli, MD, PhD

Lobar and sublobar resection with and without brachytherapy for small stage IA non– small cell lung cancer Hiran C. Fernando, FRCS, FRCSEd, Ricardo S.

Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized.

Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with.

The lord of the rings Antonio Miceli, MD, PhD

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma Paul C. Lee, MD, Farooq M. Mirza, MD, Jeffrey.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

Military surgeons just want to have fun

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

A first start for lung transplantation?

Arterial lactate before initiation of venoarterial extracorporeal membrane oxygenation for postcardiotomy shock improves postimplant outcome prediction

Stephen R. Broderick, MD, MPHS

Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology.

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

It’s All in the “Swerve of the Curve”

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Pulmonary Resection for Metastases from Colorectal Cancer

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Prognosis and “granularity”: Building on staging foundations?

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

The harder one looks, the more one finds

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Raja M. Flores, MD, Bernard J

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Junaid Haroon, MD, Subroto Paul, MD, MPH

Managing conflicts of interest

Aritoshi Hattori, MD, Kenji Suzuki, MD

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Who should decide margin length in pulmonary excision of lung cancer?

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB)

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Kalpaj Parekh, MD, Bryan F. Meyers, MD, G

Journal changes and initiatives

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,

Presentation transcript:

Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer Raja Flores, MD, Thomas Bauer, MD, Ralph Aye, MD, Shahriyour Andaz, MD, Leslie Kohman, MD, Barry Sheppard, MD, William Mayfield, MD, Richard Thurer, MD, Michael Smith, MD, Robert Korst, MD, Michaela Straznicka, MD, Fred Grannis, MD, Harvey Pass, MD, Cliff Connery, MD, Rowena Yip, MPH, James P. Smith, MD, David Yankelevitz, MD, Claudia Henschke, PhD, MD, Nasser Altorki, MD The Journal of Thoracic and Cardiovascular Surgery Volume 147, Issue 5, Pages 1619-1626 (May 2014) DOI: 10.1016/j.jtcvs.2013.11.001 Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Kaplan-Meier lung cancer–specific survival for all patients who underwent resection, separately for all stages and for all clinical stage I cases resected within 1 month of diagnosis. Typical carcinoids were excluded. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2014 147, 1619-1626DOI: (10.1016/j.jtcvs.2013.11.001) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Kaplan-Meier lung cancer–specific survival curve for all patients diagnosed as pathologic stage I by tumor diameter of the pathology specimen. Typical carcinoids were excluded. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2014 147, 1619-1626DOI: (10.1016/j.jtcvs.2013.11.001) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions